On August 27, 2026, BioLineRx Ltd. entered into a securities purchase agreement for a registered direct offering of 480,696 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 868,225 ADSs, along with unregistered warrants for up to 2,023,382 ADSs. The aggregate gross proceeds are expected to be approximately $3,750,000 before fees. Chardan Capital Markets LLC serves as the exclusive placement agent. Concurrently, BioLineRx amended existing warrants held by the purchaser to reduce the exercise price to $2.78 per ADS and extend the term until August 31, 2031. The offering is expected to close on or about August 31, 2026, with net proceeds intended for research and development and working capital. BioLineRx Ltd. operates in the biotechnology industry, focusing on the discovery and development of cancer therapies.

BioLineRx reported Q2 2026 net loss of $4.3 million, driven by a $0.6 million increase in R&D expenses for GLIX1 and a $0.7 million rise in G&A due to a prior-year doubtful account reversal. The company holds $13.1 million in cash as of June 30, 2026, maintaining its runway into the first half of 2027. On August 27, 2026, BioLineRx entered a definitive agreement for an offering with gross proceeds of $3.75 million, expected to close on or about August 31, 2026. Clinically, GLIX1 dosing commenced in the second cohort of its Phase 1/2a glioblastoma trial, with the third cohort expected in September. Preclinical data showed potent anti-tumor activity in TMZ-resistant GBM models and strong synergy between GLIX1 and PARP inhibitors in ovarian cancer models, prompting plans to add an ovarian cancer arm to the Phase 2a expansion. BioLineRx is a clinical-stage biopharmaceutical company developing oncology therapies including GLIX1 for glioblastoma and motixafortide.

BioLineRx Ltd. announced a registered direct offering and concurrent private placement on August 28, 2026, raising $3.75 million in gross proceeds. The company sold 1,348,921 American Depositary Shares (ADSs) at $2.78 per ADS through exclusive placement agent Chardan. Concurrently, BioLineRx issued warrants to purchase up to 2,023,382 additional ADSs at the same price and exercise level, expiring in five years. The company also amended outstanding ordinary warrants held by the investor, reducing their exercise price to $2.78 per ADS and extending expiration to August 31, 2031. This transaction resulted in the reduction of the existing At-the-Market (ATM) Facility maximum aggregate offering amount to zero. Net proceeds are intended for research and development activities, working capital, and general corporate purposes. The closing is expected on or about August 31, 2026.